Related Experiment Videos
IFN-alpha regulates IL 10 production by CML cells in vitro
G Pawelec1, E Schlotz, A Rehbein
1Tübingen Ageing and Tumour Immunology Group, Section for Transplantation Immunology, Second Department of Internal Medicine, Tübingen University Medical School, Tübingen, Germany. graham.pawelec@med.uni-tuebingen.de
Cancer Immunology, Immunotherapy : CII
|November 7, 1999
Summary
Interferon-alpha (IFN-alpha) reduces interleukin-10 (IL-10) in chronic myeloid leukemia (CML) cells while increasing interleukin-1 beta (IL-1beta). This suggests a mechanism for IFN-alpha therapy in CML by modulating immune responses.
Area of Science:
- Immunology
- Hematology
- Pharmacology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome.
- Interferon-alpha (IFN-alpha) has been used as a therapeutic agent in CML, but its precise mechanisms of action are not fully understood.
- Cytokine dysregulation, including interleukins (ILs) and tumor necrosis factor-alpha (TNF-alpha), plays a role in CML pathogenesis and immune response.
Purpose of the Study:
- To investigate the in vitro effects of IFN-alpha on the spontaneous secretion of key cytokines (IL-10, IL-1alpha, IL-1beta, TNF-alpha, IFN-gamma) by peripheral blood mononuclear cells (PBMCs) from untreated chronic phase CML patients.
- To compare the cytokine secretion profiles of CML cells with those of healthy controls in the presence and absence of IFN-alpha.
- To elucidate potential mechanisms by which IFN-alpha exerts its therapeutic effects in CML.
Main Methods:
- Isolation of PBMCs from untreated chronic phase CML patients and healthy donors.
- In vitro culture of PBMCs with and without IFN-alpha.
- Quantification of spontaneous cytokine secretion (IL-10, IL-1alpha, IL-1beta, TNF-alpha, IFN-gamma) using appropriate assays (e.g., ELISA, ELISpot).
Main Results:
- PBMCs from a subset of CML patients exhibited high spontaneous IL-10 secretion, which was significantly decreased by IFN-alpha.
- Healthy control PBMCs showed lower spontaneous IL-10 secretion, unaffected by IFN-alpha.
- IFN-alpha increased IL-1alpha secretion by CML cells but did not affect IL-1beta secretion by normal cells.
- No significant effect of IFN-alpha was observed on TNF-alpha secretion in either group.
- Spontaneous secretion of IL-1alpha or IFN-gamma by CML cells was not detected.
Conclusions:
- IFN-alpha may exert therapeutic effects in CML by reducing immunosuppressive IL-10 secretion, thereby potentially enhancing T-cell reactivity.
- The observed increase in IL-1beta secretion by IFN-alpha in CML cells could contribute to enhanced antigen presentation.
- These findings provide insights into the immunomodulatory mechanisms of IFN-alpha in CML treatment.